Somewhat Risky play with huge potential return - PT $90+
This game plan is only based on the chart action ,so do your own DD, I can be wrong . This stock has a very similar chart pattern as MARA and in did people already have made 105x in it (52 week range is $0.17-$18 ),but there are still potential left to get at least 15x more in a relatively short time frame . This chart so as MARAs(check MARA chart as well,I will post it below ) are SO similar to the price action described in the book of Laurentiu Damir "Price action breakdown" pages: 72-74 (in case if you are looking for detailed explanation) the long story short -this stock has reached (in my opinion ) maturity due to the price action and now moving in to demand zone with potential of getting at least 15x ,I know this is sound crazy , but it went up from $0.17 to $18(105x) with in 52 weeks, so everything is possible ....Please check the charts below (wait if you do not see them -I am working on them )
I am going to post few charts below please take a look (if you do not see those charts it means you got here little bit to soon and I am still working on it )
P.S. Constructive criticism is welcome .
I am going to post few charts below please take a look (if you do not see those charts it means you got here little bit to soon and I am still working on it )
P.S. Constructive criticism is welcome .
Comment:
Comment:
Comment:
Comment:
Comment:
Comment:
Comment:
Comment:
On March 3, the company released interim results from its clinical trials, which showed that the vaccine was 81% effective against COVID-19. What likely got investors even more bullish was news that it also showed "significant immunogenicity against the rapidly emerging variants."
The vaccine showed a higher rate of effectiveness than the COVID-19 vaccine from Johnson & Johnson, which has received an EUA and is just 66% effective (both Moderna and Pfizer have efficacy rates of more than 90%). And again, Ocugen's stock rose as much as 46% during the day, while a trading volume of 181 million soared to more than 10 times the previous day's levels.
In February, Bharat secured a deal to supply the Brazilian Health Ministry with 20 million doses of its vaccine, worth approximately $290 million. That averages out to a price of $14.50 per dose. If Bharat can produce 700 million doses of the vaccine by the end of the year, that could generate more than $10 billion in sales -- if it sells all of them at that average price.
The vaccine showed a higher rate of effectiveness than the COVID-19 vaccine from Johnson & Johnson, which has received an EUA and is just 66% effective (both Moderna and Pfizer have efficacy rates of more than 90%). And again, Ocugen's stock rose as much as 46% during the day, while a trading volume of 181 million soared to more than 10 times the previous day's levels.
In February, Bharat secured a deal to supply the Brazilian Health Ministry with 20 million doses of its vaccine, worth approximately $290 million. That averages out to a price of $14.50 per dose. If Bharat can produce 700 million doses of the vaccine by the end of the year, that could generate more than $10 billion in sales -- if it sells all of them at that average price.
Comment:
Comment: